- Trial phase
- Approved
- Time to market
- Already on the market, FDA approved June 28, 2006; now in the generic-erosion phase of its life cycle.
- Why 2/10
- No hard, dated catalyst for Sprycel in the next ~12 months: the drug was FDA-approved June 28, 2006 and is now an off-patent, generically-eroded product whose Q2 2026 revenue fell 27% YoY, a minor legacy line inside a ~$129B diversified BMY, so the impact score is 2 (small part of a large pipeline, nothing scheduled).
Do not trade BMY on Sprycel news, the binary (approval) passed 20 years ago and its erosion is immaterial to a ~$129B market-cap company whose stock is driven by the Growth Portfolio (Opdivo, Reblozyl, Eliquis, etc.). Track it only as a line in BMY's Legacy Portfolio in quarterly filings; BMY's real near-term FDA catalysts are other drugs: iberdomide PDUFA August 17, 2026, Reblozyl March 11, 2027, and mezigdomide May 13, 2027.
Price Chart
Executive Summary
Sprycel (dasatinib) is Bristol-Myers Squibb's older-generation BCR-ABL inhibitor for CML and Philadelphia chromosome-positive ALL, FDA-approved in June 2006. It is now off patent: BMY's Q2 2026 earnings materials (8-K filed July 30, 2026) report Sprycel revenue fell 27% YoY on generic erosion, within a Legacy Portfolio that was down 4% overall. For a diversified ~$129B BMY trading near $65 with a consensus "hold" rating, Sprycel is a mature, declining legacy product with no pending regulatory decision and no meaningful share-price catalyst, the approval binary passed two decades ago.
How It Works
Sprycel is an oral pill (a "tyrosine kinase inhibitor") that blocks BCR-ABL, the abnormal enzyme produced by the "Philadelphia chromosome" that drives chronic myeloid leukemia (CML) and some acute lymphoblastic leukemia (ALL). By shutting off that growth signal it slows or stops the leukemia, and it is taken daily at home.
Trial Status
No BMS-sponsored pivotal dasatinib trials appear in SecBot's ClinicalTrials.gov feed, the remaining studies are investigator-initiated Phase 2/3 efforts (e.g., OPTIM DASATINIB in CML, dasatinib+quercetin in NASH/liver fibrosis, dasatinib in aging/senescence pilots), all completed and none a company-level catalyst. Regulatory status: marketed; BMY's Q2 2026 8-K shows Sprycel revenue down 27% YoY on generic competition.
The Two-Sided Case
Upcoming Catalysts
- None for Sprycel itself, no PDUFA, pivotal readout, or regulatory decision scheduled in the next ~12 months.
- Company-level context only: iberdomide PDUFA Aug 17, 2026; Reblozyl PDUFA Mar 11, 2027; mezigdomide PDUFA May 13, 2027.
- Quarterly Legacy Portfolio reporting (next 10-Q / earnings 8-K) will show continued Sprycel erosion magnitude.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report